Month: April 2023

  Announcing Cricket 24Cricket goes global! Including The Ashes, Big Bash, The Hundred, Caribbean Premier League, and a host of international squads, plus yet to be announced professional Indian T20 teams! Cricket 24 will have more licenses than any cricket video game ever. Melbourne, April 4: Big Ant Studios and Nacon are excited to announce that Cricket 24: Official Game of The Ashes is set to release this June. Cricket 24 reimagines and enhances the much loved Cricket 22 to include teams from every corner of the globe, creating the most complete video game simulation of cricket seen to date. From the cover through to each immersive game mode in Cricket 24, Big Ant Studios continue their commitment to equality and equal representation with both the Men’s and Women’s cricket having equal representation throughout. Building the most realistic...

WISeKey International Holding Ltd to Hold Extraordinary General Meeting of Shareholders on April 27 WISeKey’s Board of Directors Recommends Shareholders Vote “FOR” All Proposals Submitted Zug, Switzerland, April 4, 2023 – WISeKey International Holding Ltd (“WISeKey” or “Company”) (SIX: WIHN, NASDAQ: WKEY), a leading global cybersecurity and IoT company, announced today that the Board of Directors has recommended to shareholders to vote “FOR” the proposals submitted to the Extraordinary General Meeting of Shareholders (“EGM“), which, as announced on March 30, 2023, will be held on April 27, 2023, 2pm CEST, at SIX ConventionPoint, Pfingstweidstrasse 110, 8005 Zurich, Switzerland. As previously announced, the proposals primarily relate to the distribution to shareholders and holders of American Depositary Shares (ADSs) of 20% of the outstanding...

The supervisory board of AS Tallinna Sadam (hereinafter: “Tallinna Sadam”) approved the audited annual report for 2022 presented by the management board. There are no differences in the audited financial results, compared to the 12-month unaudited financial results disclosed on 28 February 2023. In 2022, the annual revenue of Tallinna Sadam group was EUR 121.7 million (+11%), adjusted EBITDA amounted to EUR 56 million (+3%) and the profit was EUR 25.6 million (–0.1%). The volume of investments was EUR 13.9 million (–6%). Based on the dividend policy approved by the general meeting of shareholders to pay a dividend at least 70% of the profit, the management board, with the approval of the supervisory board, will propose to the general meeting of shareholders to pay a dividend of EUR 0.073 per share in 2023, totaling EUR 19.199 million,...

Two fitusiran Phase 3 studies published in The Lancet and The Lancet Haematology highlight potential to address unmet needs across all types of hemophiliaBoth Phase 3 studies achieved their primary and secondary endpoints; fitusiran prophylaxis demonstrated significant and clinically meaningful improvements in bleed protection across all hemophilia populations, presented at ASH 2021Paris – April 4, 2023 – Two studies, published in The Lancet and The Lancet Haematology, evaluating the efficacy and safety of fitusiran, an investigational siRNA therapy for the prophylactic treatment of adults and adolescents with hemophilia A or B, reinforce the potential of this investigational therapy to transform the current standard of care and address unmet needs for all types of hemophilia, regardless of inhibitor status. Hemophilia A and B are...

Dear shareholder! The management board of AS Tallinna Sadam (hereinafter: Tallinna Sadam), registry code 10137319, address Sadama 25, 15051 Tallinn, hereby calls the annual general meeting of shareholders, to be held at 14.00 on 25 April 2023 in the cruise terminal at Old City Harbour (Logi street 4/2, Tallinn). Registration of participants will start at the venue of the meeting on 25 April 2023 at 13.15. The list of shareholders entitled to participate at the annual general meeting will be fixed seven days before the general meeting, i.e., as of 18 April 2023 at the end of the business day of the Nasdaq CSD settlement system. As of the date of publication of this notice, the share capital of AS Tallinna Sadam is 263,000,000 euros. AS Tallinna Sadam has 263,000,000 ordinary shares, each share giving 1 (one) vote at the general meeting. In...

VEON Ltd. and VEON Holdings B.V. VEON’s 2023 Notes are amended Amsterdam, Netherlands, 4 April 2023: VEON Ltd. (NASDAQ, Euronext Amsterdam: VEON), a global digital operator that provides converged connectivity and online services, and its subsidiary, VEON Holdings B.V. (the “Company”), are pleased to announce that, further to the announcement issued on 3 April 2023 regarding the satisfaction of the Amendment Conditions, each of the steps required to implement the Amendments have been completed and, therefore, the amendments to the terms of the 2023 Notes and the 2023 Notes Trust Deeds (as set out in the Scheme) have today become effective. Therefore, the Amendment Effective Time under the Scheme has occurred. Anticipated process and timelineThe table below sets out the anticipated key dates in respect of the exercise of the Put Right.Key...

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 4, 2023 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced data showing that dipraglurant could have beneficial effects on non-motor symptoms (NMS) experienced by Parkinson’s patients in addition to its established positive effects on dyskinesias. Dipraglurant is an mGlu5 negative allosteric modulator (NAM) that has successfully completed a Phase 2a study in Parkinson’s disease patients suffering from levodopa induced dyskinesia (PD-LID). “For some time, we have known that excessive glutamate activity from degeneration of the nigro-striatal dopamine pathway has played a key role in the negative impact of motor symptoms, NMS and dyskinesias in...

PRESS RELEASE: 4 April 2023, 07:00 CEST Biocartis and APIS Assay Technologies Sign Collaboration to Develop and Commercialise a Breast Cancer Subtyping Test on the Idylla™ platform Mechelen, Belgium, 4 April 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), and APIS Assay Technologies Ltd., a private UK based company specializing in molecular diagnostics, today announce that they have entered into a new partnership agreement which targets the development of APIS’ Breast Cancer Subtyping assay on Biocartis’ rapid and easy-to-use molecular diagnostics platform Idylla™. Under the terms of the partnership agreement, APIS will lead the development of the Breast Cancer Subtyping test on Idylla™, while Biocartis will lead the commercialisation...

SIOUX FALLS, S.D. and BUTTE, Mont., April 03, 2023 (GLOBE NEWSWIRE) — NorthWestern Corporation d/b/a NorthWestern Energy (Nasdaq: NWE) and certain parties reached a settlement agreement in its Montana electric and natural gas regulatory rate review that has been submitted to the Montana Public Service Commission (MPSC) for its consideration. In addition to NorthWestern, settling parties include the Montana Consumer Counsel, the Montana Large Customer Group, the Federal Executive Agencies and Walmart Inc. The settlement includes, among other things, agreement on electric and natural gas base revenue increases, allocated cost of service, rate design, updates to the base amount of revenues associated with property taxes and electric supply costs, and regulatory policy issues related to requested changes in regulatory mechanisms. If...